Abivax Resumes Trading on Euronext Paris

Abivax, a biotechnology company in clinical stages, announced the resumption of trading for its ordinary shares on Euronext Paris. The trading is set to recommence on July 1, 2026, at 3:30 p.m. CEST. Prior to this, trading was halted since 9:00 a.m. CEST on the same day at the company's request. This pause was linked to a public offering involving American Depositary Shares in the United States, facilitating allocations and pricing announcements.

Abivax's focus is on developing treatments to stabilize immune responses in chronic inflammatory conditions. The company has operations in both France and the United States, with its lead candidate, obefazimod, undergoing Phase 3 trials for ulcerative colitis.